title: Characteristic pattern of reactivation of hepatitis B virus during chemotherapy for solid cancers.
abstract: OBJECTIVE
  A number of studies have reported reactivation of hepatitis B during intensive immunosuppressive therapy such as cases of hematological malignancy, whereas little has been reported for characteristics of reactivation triggered by chemotherapy for solid cancer.
  
  
  METHODS
  A total of 130 patients underwent chemotherapy for treatments of common solid cancer between May 2011 and May 2012 at Kinki University Hospital. Among them, 27 patients were suspected for a past infection of hepatitis B virus (HBV), showing positive for hepatitis B core antibody or surface antibody but negative for hepatitis B surface antigen, and were eligible for this study.
  
  
  RESULTS
  Hepatitis B reactivation was observed in 2 of 27 cases (7.4%). The duration between the start of chemotherapy and increase of serum HBV load was 30 days in both cases.
  
  
  CONCLUSIONS
  We reported the 2 cases of hepatitis B reactivation receiving chemotherapy for solid cancer in terms of patterns and characteristics of reactivation. Accumulation of such cases will help in clarifying the clinical importance of hepatitis B reactivation during treatment of solid malignancies.
authors.affiliation: Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japan.
authors.forename: Satoru
authors.initials: S
authors.lastname: Hagiwara
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Sakurai
authors.forename: Shinichi
authors.initials: S
authors.lastname: Nishina
authors.forename: Kaoru
authors.initials: K
authors.lastname: Tanaka
authors.forename: Masafumi
authors.initials: M
authors.lastname: Ikeda
authors.forename: Kazuomi
authors.initials: K
authors.lastname: Ueshima
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Minami
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Inoue
authors.forename: Norihisa
authors.initials: N
authors.lastname: Yada
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kitai
authors.forename: Masahiro
authors.initials: M
authors.lastname: Takita
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Nagai
authors.forename: Sousuke
authors.initials: S
authors.lastname: Hayaishi
authors.forename: Tadaaki
authors.initials: T
authors.lastname: Arizumi
authors.forename: Ah-Mee
authors.initials: AM
authors.lastname: Park
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Munakata
authors.forename: Naoshi
authors.initials: N
authors.lastname: Nishida
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kudo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006509:Hepatitis B / Q000150:complications / Q000821:virology*; D006515:Hepatitis B virus / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy*; D019562:Viral Load; D014775:Virus Activation
chemical_list: D000970:Antineoplastic Agents; D004279:DNA, Viral